- Home
- HURA vs ATOS Comparison
HURA vs ATOS Comparison
Compare HURA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- ATOS
- Stock Information
- Founded
- HURA 2009
- ATOS 2009
- Country
- HURA United States
- ATOS United States
- Employees
- HURA N/A
- ATOS N/A
- Industry
- HURA
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- HURA
- ATOS Health Care
- Exchange
- HURA Nasdaq
- ATOS Nasdaq
- Market Cap
- HURA 126.1M
- ATOS 112.7M
- IPO Year
- HURA N/A
- ATOS 2012
- Fundamental
- Price
- HURA $2.59
- ATOS $1.07
- Analyst Decision
- HURA Strong Buy
- ATOS Strong Buy
- Analyst Count
- HURA 2
- ATOS 3
- Target Price
- HURA $11.50
- ATOS $6.25
- AVG Volume (30 Days)
- HURA 214.3K
- ATOS 796.0K
- Earning Date
- HURA 11-13-2025
- ATOS 11-11-2025
- Dividend Yield
- HURA N/A
- ATOS N/A
- EPS Growth
- HURA N/A
- ATOS N/A
- EPS
- HURA N/A
- ATOS N/A
- Revenue
- HURA N/A
- ATOS N/A
- Revenue This Year
- HURA N/A
- ATOS N/A
- Revenue Next Year
- HURA N/A
- ATOS N/A
- P/E Ratio
- HURA N/A
- ATOS N/A
- Revenue Growth
- HURA N/A
- ATOS N/A
- 52 Week Low
- HURA $1.80
- ATOS $0.55
- 52 Week High
- HURA $8.40
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- HURA 45.68
- ATOS 78.83
- Support Level
- HURA $2.38
- ATOS $0.86
- Resistance Level
- HURA $2.66
- ATOS $1.05
- Average True Range (ATR)
- HURA 0.12
- ATOS 0.05
- MACD
- HURA 0.01
- ATOS 0.02
- Stochastic Oscillator
- HURA 42.86
- ATOS 95.23
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.